Sedación consciente vs anestesia general en el TAVI

SOLVE-TAVI after 12-month followup: self-expanding vs. balloon expandable and general vs. local anesthesia

The ambitious SOLVE-TAVI (soon to be published in JACC) is aimed at answering to of the most important questions we make when facing a TAVR procedure: What valve do we choose, a self-expanding or a balloon expandable? And once we have chosen our device, do we proceed with general anesthesia or conscious sedation?    The<a href="https://solaci.org/en/2021/05/04/solve-tavi-after-12-month-followup-self-expanding-vs-balloon-expandable-and-general-vs-local-anesthesia/" title="Read more" >...</a>

Incidence, Predictors, and Results of Acute Kidney Injury in Patients Undergoing TAVR

Acute kidney injury after transcatheter aortic valve replacement (TAVR) is a well-known adverse event for all interventional cardiologists. However, it has been understudied: only small observational research has been conducted, showing too wide incidence rates. This research included all patients who underwent TAVR in the USA between 2016 and 2018, totaling over 100,000 patients. All subjects<a href="https://solaci.org/en/2021/05/03/incidence-predictors-and-results-of-acute-kidney-injury-in-patients-undergoing-tavr/" title="Read more" >...</a>

duración terapia de doble antiagregación plaquetaria

Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement (TAVI). Some recent data finally condensed in the present meta-analysis and recently published in JAHA happen to challenge these guidelines.  Clinical studies that investigated single antiplatelet therapy versus DAPT until November 2020 were analyzed and divided according to<a href="https://solaci.org/en/2021/04/26/dual-antiplatelet-therapy-and-tavr-obsolete-guidelines/" title="Read more" >...</a>

CT and Angiography Agreement in Patients from the ISCHEMIA Trial

Computed tomographic (CT) angiography showed a high degree of agreement with conventional angiography to detect significant coronary artery disease and rule out left main disease. This imaging study was done on a group of patients before their randomization in the ISCHEMIA trial. Data are soon to be published in JACC Cardiovascular Imaging and add plenty<a href="https://solaci.org/en/2021/04/23/ct-and-angiography-agreement-in-patients-from-the-ischemia-trial/" title="Read more" >...</a>

Cerebral Protection Devices during TAVR in the Daily Practice

The theory behind the use of cerebral protection devices during TAVR is good, but hard to test. The daily practice provides a far bigger number of patients, and therefore might be able to better show how to prevent one of the hardest events during TAVR.  This study resorted to Germany’s TAVR database between 2015 and<a href="https://solaci.org/en/2021/04/21/cerebral-protection-devices-during-tavr-in-the-daily-practice/" title="Read more" >...</a>

pacientes anticoagulados por fibrilación auricular que reciben angioplastia tratamiento

The Best Anticoagulant Agent for AF After TAVR

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation (AF) discharged after transcatheter aortic valve replacement (TAVR), compared with classic vitamin K antagonists. The purpose of this paper published in JACC Interv was to compare long-term results between classic vitamin K antagonists and novel direct anticoagulant agents in patients with<a href="https://solaci.org/en/2021/04/15/the-best-anticoagulant-agent-for-af-after-tavr/" title="Read more" >...</a>

Es un hecho: la protección cerebral en TAVI logró demostrar que reduce el stroke y la muerte

Silent Stroke During TAVR and Early Cognitive Impairment

Silent stroke is common after transcatheter aortic valve replacement (TAVR). Co-morbidities such as diabetes or chronic renal failure, as well as procedural factors such as pre-dilation, increase the risk of silent stroke. While many events of silent stroke have an early effect on cognition, it is necessary to learn whether the impairment is sustained over<a href="https://solaci.org/en/2021/04/14/silent-stroke-during-tavr-and-early-cognitive-impairment/" title="Read more" >...</a>

The Most Read Articles on Interventional Cardiology of March

The Most Read Articles in Interventional Cardiology of March

01- Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement. Read more HERE 02- Major Cause of Myocardial Injury by COVID-19 The most common cause of myocardial necrosis in patient undergoing COVID-19 infection is microthrombi. These<a href="https://solaci.org/en/2021/04/07/the-most-read-articles-in-interventional-cardiology-of-march/" title="Read more" >...</a>

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

SCOPE I: Acurate NEO vs Sapien 3, no non-inferiority at one year?

The randomized controlled study SCOPE 1 failed to show significant differences at one year between the self-expandable Acurate neo and the balloon expandable Sapien 3.  The SCOPE 1 (Safety and Efficacy of the Symetis ACURATE neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis) compared the balloon expandable Sapien 3 (which has probably more data) against<a href="https://solaci.org/en/2021/03/30/scope-i-acurate-neo-vs-sapien-3-no-non-inferiority-at-one-year/" title="Read more" >...</a>

Es posible esterilizar las máscaras N95 y los barbijos quirúrgicos

Efficacy of Mass Vaccination with Pfizer/BioNTech against COVID-19 in Israel

We need to know how effective vaccines are by population subgroup outside the controlled setting of a clinical trial.  Israel was one of the first countries to deploy a nationwide mass vaccination strategy. This is why it results ideal to compare its results against clinical trial results.  All subjects receiving the BNT162b2 mRNA Covid-19 Vaccine<a href="https://solaci.org/en/2021/03/29/efficacy-of-mass-vaccination-with-pfizer-biontech-against-covid-19-in-israel/" title="Read more" >...</a>